Argenx

This study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases known as idiopathic inflammatory myopathy (IIM). Only people who completed an earlier study of this drug can join. Participants will receive the drug for up to 51 mon…

This study tested an experimental drug called ARGX-119 in 60 adults with ALS to see if it was safe and could slow the disease. The trial was stopped early because early results showed the drug was unlikely to help patients meaningfully. No safety concerns caused the early stop, a…

This study tests a drug called efgartigimod for adults with ocular myasthenia gravis, a condition that causes eye muscle weakness like droopy eyelids or double vision. About 141 people will take part. In the first 7 weeks, half get the drug and half get a placebo; after that, eve…

This study looks at the long-term safety and effects of a drug called ARGX-117 in adults with multifocal motor neuropathy, a condition that causes muscle weakness. About 51 people who completed an earlier trial will receive the drug intravenously over an extended period. The goal…

This study tests an experimental drug called ARGX-117 in people who receive a kidney from a deceased donor and are at risk for delayed graft function (when the kidney takes time to start working). About 103 participants will get either the drug or a placebo, and researchers will …

This study tests an investigational drug called efgartigimod in adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities and muscle strength. Abou…

This study tests a new medicine called empasiprubart against a placebo in adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. About 3 participants will receive the drug or placebo for 25 weeks, then be followed for safety over a year. The goal is …

This study tests a drug called efgartigimod in 631 adults with moderate-to-severe primary Sjögren's disease, an autoimmune condition causing dry eyes and mouth. The trial is double-blind and placebo-controlled, meaning some get the drug and some get a dummy shot, with an open-lab…

This study tests a drug called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if the drug is safe and helps maintain healthy platelet levels over a year. Partici…

This study looks at the long-term safety of a drug called efgartigimod in children with generalized myasthenia gravis, a disease that causes muscle weakness. About 12 children who already took part in earlier studies will continue receiving the drug either through a vein or as a …

This study follows 413 adults with multifocal motor neuropathy (MMN) over time to learn how the disease progresses and affects daily life. Researchers will collect information on symptoms, quality of life, and healthcare costs during regular doctor visits. No experimental treatme…